We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

NHF Comments on Trump Administration Drug Pricing Blueprint

NHF submitted a letter on the "American Patients First" drug pricing blueprint.

HTRS

The HTRS MRA provides financial support for qualified fellows or junior attending/junior faculty pursuing clinical, translational, or basic science research in hemostasis and/or thrombosis under the guidance of an experienced mentor.

Study Shows Impact of Missing HTC Clinic Visits

New study from Emory University School of Medicine focused on causes and ramifications of missing clinic visits in patients with bleeding disorders.

The rate of attendance to scheduled clinic visits have been linked to health outcomes in several chronic disease groups such as diabetes, hypertension, HIV and congenital heart disease. Higher clinic attendance rates are generally associated with better outcomes in these patients. However, the potential effects of non-attendance (NA) for individuals with bleeding disorders is not well understood.

Pfizer Initiates First Stage of Phase 3 Hemophilia B Gene Therapy Trial

The first stage will collect data that will be eventually used to evaluate the efficacy and safety of the investigational hemophilia B therapy.

Subscribe to Our Newsletter

Fill in the fields below to receive our email newsletter.